In Silico Evaluation of the Potential Antiarrhythmic Effect of Epigallocatechin-3-Gallate on Cardiac Channelopathies

Table 1

Formulation of WT and mutated sodium channels (-p.R222Q and -p.I141V) in the presence or absence of 30 µM of E3G. The bold font corresponds to mutations effect and the bold-italic font to E3G effects.

	TNNP/SANNBZ models, p.R222Q.	TNNP/SANNBZ models, p.I141V.	TNNP/SANNBZ models,	TNNP/SANNB models,
WT	, WT () = , WT (); , WT () = , WT (); WT () = , WT (); , WT () = , WT (); WT () = , WT ()	, WT () = , WT (); , WT () = , WT (); WT () = , WT (); , WT () = , WT (); WT () = , WT ()	100% of	100% of
WT + 30 µM E3G	, WT () = , WT (); , WT () = , WT (); WT () = , WT (); , WT () = , WT ( + 6); WT () = , WT ()	, WT () = , WT (); , WT () = , WT (); WT () = , WT (); , WT () = , WT ( + 6); WT () = , WT ()	80% of	50% of
Mutants	, p.I141V () = , WT	, p.I141V () = , WT ()	100% of	100% of
	, p.I141V () = , WT ()	, p.I141V () = , WT
	, p.I141V () = , WT ()	, p.I141V () = , WT ( + 7)
	, p.I141V () = , WT ( + 6.2); WT () = , WT ()	, p.I141V () = , WT (); WT () = , WT ( + 7)
Mutants + 30 µM E3G	, p.I141V () = , WT	, p.I141V () = , WT	80% of	50% of
	, p.I141V () = , WT ()	, p.I141V () = , WT
	, p.I141V () = , WT ()	, p.I141V () = , WT ( + 7)
	, p.I141V () = , WT ( + 6.2 + 6)	, p.I141V () = , WT ( + 6)
	WT () = , WT ()	WT () = , WT ( + 7)